Background
Multidrug resistance (MDR) TB is on the rise globally and is associated with significant morbidity and mortality. Conventional culture based drug susceptibility testing (DST) for TB drugs is time consuming, leading to diagnostic delays contributing to higher TB morbidity and mortality and exacerbation of ongoing transmission. Moreover most of the NTM(Non tuberculous mycobacteria) that are resistant to common anti tB drugs, can be falsely labeled as MDR tB if not identified correctly. This study was aimed to identify Mycobacterium species and to determine the prevalence of multidrug resistant tuberculosis (MDR tB) by line probe assay.
Methods
This study was done on 76 clinical isolates collected from TB patients who were on Anti tuberculous drug treatment since last six months but without any clinical improvement. Line probe assay was performed for detection, identification of species and drug susceptibility status.
Anzeige
Results
Line probe assay detected 49 isolates (96%) of M. tuberculosis, 1 isolate (1.96%) of M. avium and M. intracellulare each. Out of 49 isolates of M.tuberculosis 9(18.4%) were Rifampicin resistant and 11(22.4%) INH resistant but what was alarming was that 9 isolates (18.4%) were MDR.
Conclusion
The majority of multidrug resistant TB cases are due to ongoing transmission of multidrug resistant strains. This is most likely the result of diagnostic delay, thereby emphasizing the need for rapid diagnostics and line probe assay can be used for the rapid identification of Mycobacterium species and the determination of susceptibility to drugs, which may accelerate the time to effective MDR tB treatment.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.